Coverage complications are not unusual in the U.S. health care system. But the challenge is magnified for these obesity ...

Medicare spending on some diabetes drugs, including popular treatments such as Ozempic, surged nearly five-fold to $35.8 ...

The FDA’s decision will threaten the ability of compounding pharmacies to make far cheaper, unbranded versions of the ...

Many employers and insurers are scaling back coverage of Wegovy and Zepbound and a key government program, Medicare, doesn’t cover the drugs for obesity. Meanwhile, some big employers are adding ...

The assassination of UnitedHealthcare CEO Brian Thompson triggered a disturbing avalanche of sympathy for the suspected ...

The Trump administration, perhaps surprisingly, chose to defend the legality of the Inflation Reduction Act’s (IRA’s) drug ...

The Food and Drug Administration said on Friday that there is no longer a shortage of drugs like Wegovy and Ozempic. The semaglutide known as Ozempic is intended to be used for people with diabetes.

This will be a “pivotal year,” one expert says, for GLP-1 drugs, which are massively disrupting the benefits landscape.

If the CMS rule to cover obesity medications is finalized, coverage will increase by other insurers, experts predicted. HHS ...